Given the quick max out on the ATM with the key binary data due so soon (later this quarter) and combined with skipping that final interim efficacy analysis, my gut is this all doesn't bode as the best sign for that pending P3 data. But, doesn't mean doomed for failure either. Still, I don't think I'm willing to gamble on that P3 data myself (stock certainly seems really cheap if the P3 data is positive though).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.